GPX1 and acute myeloid leukemia: Since the metabolomic, proteomic, and transcriptomic analyses suggested the possible relevance of Gpx1 in BMSC-dependent AML protection from chemotherapy, the Gpx1 inhibitor mercaptosuccinic acid (MSA) was tested in culture.